News

The U.S. Food and Drug Administration (FDA) has approved Milla Pharmaceuticals’ generic version of Mestinon (pyridostigmine bromide) for treating the symptoms of myasthenia gravis (MG). The new generic, available as a syrup, is expected to soon launch in the U.S. This approval of Milla’s abbreviated new drug…

Rates of long-term disease remission after thymectomy — thymus removal surgery — among people with myasthenia gravis (MG) are lower than rates of remission over the first year after the procedure, according to a real-world study. Most clinical factors, such as disease type, age, or sex were…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Fufang Huangqi decoction — a traditional Chinese medicine formula reported to reduce symptoms of myasthenia gravis (MG) — helps to restore the balance of gut microbial community, or microbiota, in people with mild MG, according to a small study. These early findings suggest that the formula’s clinical benefits may…

The dynamics of mitochondria — the cells’ powerhouses — and their associated energy metabolism are highly affected in people with myasthenia gravis (MG), a study shows. Notably, the levels of several proteins involved in mitochondrial dynamics and health were found to be significantly reduced in MG patients, and many of…

The National Organization for Rare Disorders (NORD) has updated its State Report Card to make it more digitally friendly and added telehealth to its categories of rare disease policy issues in a nod to its increased use during the ongoing COVID-19 pandemic. NORD’s report card project began seven…

Long-term treatment with Vyvgart (efgartigimod alfa-fcab) is safe and well tolerated, and leads to a sustained improvement in generalized myasthenia gravis (gMG) disease scores. These findings come from an interim analysis of ADAPT+ (NCT03770403), an ongoing Phase 3, open-label, three-year extension of ADAPT (NCT03669588) that is…

Treatment with Ultomiris (ravulizumab-cwvz) eased symptoms of generalized myasthenia gravis (gMG) for more than a year, according to new data from the ongoing CHAMPION-MG extension study. Findings were shared at the 2022 American Academy of Neurology (AAN) Annual Meeting in an oral presentation, titled “Long-term Efficacy and Safety of…

More or larger clusters of developing B-cells, called germinal centers, in the thymus may predict better outcomes after thymus removal surgery in people with myasthenia gravis (MG), according to a recent study that utilized modern tools of digital pathology to support its findings. “Digital pathology can thus help in…

Myasthenia gravis (MG) may occur alongside Miller Fisher syndrome, another rare autoimmune disease also characterized by weakness of the eye muscles, a recent case report highlights. The report emphasizes the importance of careful examination for the possibility of co-occurring autoimmune disorders when a patient shows uncommon symptoms. “Even…